A Phase I Study to Evaluate Safety and Pharmacokinetics of Escalating Single Doses and Multiple Doses of SP-8356

PHASE1

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Only Part 1 was conducted but not Part 2. Due to the low exposures, definitive safety conclusions could not be made for the targeted exposure levels in the future.

Conditions

Atherosclerosis
Ischemic Stroke

Interventions

DRUG: SP-8356
DRUG: Placebo

Sponsor

Shin Poong Pharmaceutical Co. Ltd.